NCT07589595: A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
- State
- Under way
- Phase
- Phase 2
- People
- 350 planned
- Started
- 20 May 2026
- Primary completion
- Aug 2028
- Arms
- Donanemab (LY3002813)
- Results
- None posted
- 15 May 2026: Trial registered
- 20 May 2026: Trial started